跳至主要内容
临床试验/EUCTR2013-001258-82-IT
EUCTR2013-001258-82-IT进行中(未招募)不适用

A phase II pilot clinical study of experimental research to evaluate thefunctional rescue of CFTR protein through proteostasis regulators - Proteostasis regulators effect in cystic fibrosis therapy

European Institute for Cystic Fibrosis Research (IERFC)0 个研究点开始时间: 2013年7月29日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Diagnosis of cystic fibrosis by sweat test with chloride level=60 mEq/l and confirmed by genetic analysis in order to search cystic fibrosis F508del-CFTR homozigotic mutation or F508del-CFTR combined mutations of class I and II
  • - males or females aged at least 6 years old.
  • - fertile females should accept a contraceptive method.
  • - FEV1 =40% as compared to expected value for age and sex.
  • - At least 2 sweat tests within the 3 months before Meeting 1 to
  • establish the interindividual variation of chloride level in the sweat.
  • -Informed agreement
  • - All subjects must be able to understand the aim of the study
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 60
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 7
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Treatment with glucocorticoids per os or via inhalationat Meeting 1 or within 4 weeks before meeting 1.
  • - Treatment with oxygen, over day or over night.
  • - Other experimental drugs.
  • - Hypersensitivity (local or general) to cysteamine or penicillamine.
  • - Modifications in the therapy with macrolides, ant-asmatic, mucolytic
  • drugs, Dornase alfa, and/or FANS, DHA within 28 days before Meeting 1.
  • However, ita can be accepted the use of some drugs (for example FANS).
  • - Lung/hepatic/other organ transplantation.
  • - Kidney or hepatic alterations at Meeting 1:
  • -AST, ALT > 5 fold normal value . -
  • Creatinine > 2 fold normal value (ULN).
  • - Pregnancy
  • - Nursing.
  • - No contraceptive method.
  • - Neurologic and psychiatric pathologies that, on the basis of the Researcher
  • experience, could interfere with protocol

研究者

发起方
European Institute for Cystic Fibrosis Research (IERFC)

相似试验

进行中(未招募)
1 期
A phase II clinical trial to assess the effect of HC-SVT-1001 and HC-SVT-1002 in the surgical treatment of nonunions fractures of long bonesAtrophic pseudarthrosisMedDRA version: 21.1Level: PTClassification code 10048617Term: PseudarthrosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2013-000930-37-ESaboratorios Salvat, S.A.12
招募中
2 期
Acute Renal effects of Angiotensin II Management In Shock (ARAMIS-2)Vasodilatory shockRenal and Urogenital - Kidney diseaseCardiovascular - Diseases of the vasculature and circulation including the lymphatic system
ACTRN12621001043820Austin Health150
进行中(未招募)
1 期
A Phase II Pilot Study to Assess Safety and Efficacy of Sodium Valproate in Adults with McArdle DiseaseMcArdle disease (Glycogen storage disease type V, GSDV). The condition is an inherited disorder of skeletal muscle that causes exercise intolerance. The condition can give way to potential rhabdomyolysis which can cause acute renal failure and from middle age muscle wasting and weakness. Affected patients are unable to produce lactate during ischaemic exercise due to a congenital lack of the enzyme muscle glycogen phosphorylase which is essential for glycogen metabolism.MedDRA version: 16.1 Level: LLT Classification code 10026969 Term: McArdle's disease System Organ Class: 100000004850
EUCTR2012-002933-12-GBniversity College London,8
已完成
2 期
Permissive Hypercapnia, Alveolar Recruitment and Limited Airway Pressures reduce injury in Acute Respiratory Distress Syndrome.Acute respiratory distress syndrome.Respiratory - Other respiratory disorders / diseases
ACTRN12607000465459Intensive Care Unit, Alfred Hospital20
尚未招募
不适用
A short-term ketogenic diet combined with 24-hour fasting and chemoprotection for patients with acute myeloid leukaemiaacute myeloid leukemia
ACTRN12620000850976epean Blue Mountains Local Health District134